Parkinson’s disease
Clinical research activity is centered on Parkinson’s disease, with interest in therapies that support symptom management through transdermal delivery approaches. The current trial focus reflects evaluation of a rotigotine patch in people living with this neurological disorder.
- Rotigotine patch adherence
- Transdermal therapy
- Neurology
Research attention is directed toward treatment delivery features relevant to motor symptom care in Parkinson’s disease, with a specific emphasis on patch performance in clinical use.
Dermal patch performance
The sponsor’s clinical interest includes the skin adhesion characteristics of a transdermal patch, a key consideration for sustained drug delivery in chronic neurological therapy. This area links pharmaceutical development with practical wearability in everyday treatment.
- Skin adhesion
- Patch retention
- Transdermal formulation
Focus is placed on how the patch remains attached over the dosing interval, supporting reliable administration of rotigotine through the skin.
Comparative pharmaceutical evaluation
Clinical work also involves comparative assessment between a test product and a reference product, reflecting interest in the performance of alternative transdermal formulations. This supports the evaluation of product consistency within drug delivery development.
- Reference product comparison
- Formulation performance
- Transdermal comparison
The research setting includes multiple collaborating sites in Switzerland, indicating coordinated clinical assessment within a focused therapeutic area.
